Designation of Chenodeoxycholic acid as an orphan drug by Link Healthcare

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, was designed to provide a regulatory framework for therapeutic goods in Australia, ensuring their safety, quality, and efficacy. This Act was introduced to address the need for a comprehensive system governing the importation, supply, and advertising of therapeutic goods, thereby protecting public health. The 2016 designation of Chenodeoxycholic acid as an orphan drug under this Act by the Delegate of the Secretary, Dr Anthony Gill, highlights the policy objective of encouraging the development and availability of treatments for rare diseases. This specific designation aims to facilitate access to Chenodeoxycholic acid for the treatment of inborn errors of primary bile acid synthesis, recognising the limited patient population and the urgent need for targeted therapies. The designation is part of broader efforts to support innovation and ensure that orphan drugs meet the necessary standards for patient safety and efficacy.

Scope and Application

The Therapeutic Goods Act 1989 applies to the designation of therapeutic goods in Australia, with its administration overseen by the Therapeutic Goods Administration (TGA), a division of the Department of Health. Specifically, the Act includes provisions for the designation of orphan drugs, which are intended for the treatment of rare conditions. In this instance, Chenodeoxycholic acid has been designated as an orphan drug for the treatment of inborn errors of primary bile acid synthesis. This designation applies to the sponsor of the drug, in this case, Link Healthcare Pty Ltd, and to the specific dose form of the drug, which is a capsule. The geographic reach of the Act is national, applying across all states and territories of Australia. The Act may extend or restrict its application through subordinate instruments, such as the Therapeutic Goods Regulations 1990, which provide further detail on the processes and criteria for drug designation. This specific designation does not outline any exclusions, exemptions, or thresholds beyond the criteria necessary for orphan drug status.

Key Provisions

The main sections of the Therapeutic Goods Act 1989 that are relevant to this legislation pertain to the designation of therapeutic goods and the criteria for orphan drugs. Section 16J of the Therapeutic Goods Regulations 1990, under which this designation is made, focuses on the process for designating certain drugs as orphan drugs, particularly for rare or neglected conditions (16J(2)). In this instance, Chenodeoxycholic acid has been designated as an orphan drug for the treatment of inborn errors of primary bile acid synthesis, a rare condition that affects the production of bile acids in the body (16J(2)). The obligations imposed by this designation on the relevant parties are primarily administrative and procedural. The sponsor, Link Healthcare Pty Ltd, must ensure that the therapeutic good meets the necessary safety, quality, and efficacy standards. Additionally, the sponsor must provide comprehensive data and information to support the orphan drug status of Chenodeoxycholic acid, including clinical trial results and evidence of the drug’s effectiveness in treating the specified condition (16J(2)). The sponsor is also required to maintain records and documentation that can be audited by the Therapeutic Goods Administration (TGA) to verify compliance with the regulations. There are potential legal consequences for non-compliance with the Therapeutic Goods Act and the Therapeutic Goods Regulations. Violations may result in the TGA taking enforcement actions, such as imposing fines or issuing infringement notices. Under the Therapeutic Goods Act, penalties for breaches can include fines of up to $222,200 for individuals and $1,111,000 for corporations, depending on the severity and frequency of the breach. In addition to financial penalties, there can be criminal charges for serious or repeated breaches, leading to potential imprisonment. The specific penalties are outlined in section 42A of the Therapeutic Goods Act, which details the various sanctions available for non-compliance with the Act and Regulations.